KR20160074015A - 호르몬을 조절하기 위한 방법 및 시스템 및 관련 방법, 작용제 및 조성물 - Google Patents

호르몬을 조절하기 위한 방법 및 시스템 및 관련 방법, 작용제 및 조성물 Download PDF

Info

Publication number
KR20160074015A
KR20160074015A KR1020167015704A KR20167015704A KR20160074015A KR 20160074015 A KR20160074015 A KR 20160074015A KR 1020167015704 A KR1020167015704 A KR 1020167015704A KR 20167015704 A KR20167015704 A KR 20167015704A KR 20160074015 A KR20160074015 A KR 20160074015A
Authority
KR
South Korea
Prior art keywords
bitter
receptor
bitter taste
ligand
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167015704A
Other languages
English (en)
Korean (ko)
Inventor
윌리암 에이. 3세 고다드
마크 멘나
스티븐 팬돌
라빈더 아브롤
Original Assignee
캘리포니아 인스티튜트 오브 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캘리포니아 인스티튜트 오브 테크놀로지 filed Critical 캘리포니아 인스티튜트 오브 테크놀로지
Publication of KR20160074015A publication Critical patent/KR20160074015A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A61K47/4823—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
KR1020167015704A 2010-06-17 2011-06-17 호르몬을 조절하기 위한 방법 및 시스템 및 관련 방법, 작용제 및 조성물 Ceased KR20160074015A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39794010P 2010-06-17 2010-06-17
US61/397,940 2010-06-17
PCT/US2011/040994 WO2011160093A2 (en) 2010-06-17 2011-06-17 Methods and systems for modulating hormones and related methods, agents and compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137000152A Division KR20130112019A (ko) 2010-06-17 2011-06-17 호르몬을 조절하기 위한 방법 및 시스템 및 관련 방법, 작용제 및 조성물

Publications (1)

Publication Number Publication Date
KR20160074015A true KR20160074015A (ko) 2016-06-27

Family

ID=45348917

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167015704A Ceased KR20160074015A (ko) 2010-06-17 2011-06-17 호르몬을 조절하기 위한 방법 및 시스템 및 관련 방법, 작용제 및 조성물
KR1020137000152A Ceased KR20130112019A (ko) 2010-06-17 2011-06-17 호르몬을 조절하기 위한 방법 및 시스템 및 관련 방법, 작용제 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137000152A Ceased KR20130112019A (ko) 2010-06-17 2011-06-17 호르몬을 조절하기 위한 방법 및 시스템 및 관련 방법, 작용제 및 조성물

Country Status (6)

Country Link
US (4) US8796233B2 (https=)
EP (1) EP2582367A4 (https=)
JP (1) JP2013528661A (https=)
KR (2) KR20160074015A (https=)
CN (1) CN103068380A (https=)
WO (1) WO2011160093A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102140493B1 (ko) * 2019-05-30 2020-08-03 충북대학교 산학협력단 데나토늄을 유효성분으로 포함하는 골 질환의 예방 또는 치료용 조성물

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582367A4 (en) * 2010-06-17 2013-11-27 California Inst Of Techn METHOD AND SYSTEM FOR MODULATING HORMONES AND RELATED METHODS, ACTIVE SUBSTANCES AND COMPOSITIONS
MX2013004364A (es) * 2010-10-19 2013-07-02 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
EP2661266B1 (en) 2011-01-07 2020-09-16 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
EP2800562A2 (en) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
JP2014148474A (ja) * 2013-01-31 2014-08-21 Chube Univ Ｇｌｐ−１分泌促進剤
JP2015083548A (ja) * 2013-10-25 2015-04-30 花王株式会社 血中ｇｌｐ−１濃度上昇促進剤
US12551526B2 (en) * 2015-04-22 2026-02-17 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
CN105699545A (zh) * 2016-04-25 2016-06-22 广西壮族自治区梧州食品药品检验所 一种测定银马解毒颗粒中甘草酸铵含量的方法
US10835505B2 (en) 2018-06-11 2020-11-17 Aardvark Therapeutics, Inc. Oral pharmaceutical formulation for weight loss, diabetes and related disorders
US12201593B2 (en) 2018-07-02 2025-01-21 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for asthma
WO2020014494A1 (en) 2018-07-11 2020-01-16 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension
EP4034082A4 (en) 2019-09-25 2023-07-05 Aardvark Therapeutics Inc. Oral pharmaceutical immediate release composition and method of treatment for weight loss
EP4081201A4 (en) * 2019-12-24 2024-01-10 Aardvark Therapeutics Inc. Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders
ES2894177A1 (es) * 2020-08-07 2022-02-11 Univ Rovira I Virgili Composición y método para modular la ingesta de alimentos
JP2022099458A (ja) * 2020-12-23 2022-07-05 株式会社東洋新薬 グルカゴン様ペプチド－１分泌促進用組成物
CA3204811A1 (en) * 2021-02-01 2022-08-04 Zhenhuan ZHENG Denatonium salt for use in preventing, preventing progression and treating fatty liver diseases
CA3215858A1 (en) * 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039933A (en) * 1957-10-07 1962-06-19 Premo Pharmaceutical Lab Inc Ethyl cellulose-polyethylene glycol tablet matrix
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
EP1214343A2 (en) * 1999-09-10 2002-06-19 The Regents Of The University Of California T2r taste receptor family
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US20020192310A1 (en) 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
CN1610830A (zh) 2001-07-10 2005-04-27 塞诺米克斯公司 特异性t2r味觉受体在鉴定阻断苦味觉的化合物中的应用
US20060019346A1 (en) * 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
KR100523336B1 (ko) 2003-03-12 2005-10-24 (주)바이오버드 수불용성 쿠르쿠민의 수용화 방법
US20050019435A1 (en) * 2003-07-21 2005-01-27 Jeffrey Young Method of treating non-insulin dependent diabetes mellitus and related complications
CN1676132A (zh) * 2004-03-30 2005-10-05 贵州圣济堂制药有限公司 丙硫氧嘧啶制剂及其制备方法
US7858080B2 (en) * 2005-05-20 2010-12-28 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US7390514B2 (en) 2005-11-28 2008-06-24 Sahajanand Biotech Pvt. Ltd. Herbal composition for treatment and maintenance of hormone dependent conditions, osteoporosis, circulatory conditions, and for use as an immunostimulant
EP2749552B1 (en) * 2007-04-17 2015-11-18 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
US9221877B2 (en) * 2008-09-19 2015-12-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Curcumin conjugates for treating and preventing cancers
BRPI0919648A2 (pt) * 2008-10-29 2015-12-08 Hoffmann La Roche novos derivados de fenil amida ou piridil amida e seu uso como agonistas de gpbar1
EP2924112A1 (en) * 2009-02-02 2015-09-30 Chromocell Corporation Novel cell lines and methods
EP2582367A4 (en) * 2010-06-17 2013-11-27 California Inst Of Techn METHOD AND SYSTEM FOR MODULATING HORMONES AND RELATED METHODS, ACTIVE SUBSTANCES AND COMPOSITIONS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102140493B1 (ko) * 2019-05-30 2020-08-03 충북대학교 산학협력단 데나토늄을 유효성분으로 포함하는 골 질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
US20200072832A1 (en) 2020-03-05
JP2013528661A (ja) 2013-07-11
WO2011160093A2 (en) 2011-12-22
KR20130112019A (ko) 2013-10-11
US9272051B2 (en) 2016-03-01
EP2582367A4 (en) 2013-11-27
US20160356773A1 (en) 2016-12-08
US8796233B2 (en) 2014-08-05
WO2011160093A3 (en) 2012-04-26
CN103068380A (zh) 2013-04-24
EP2582367A2 (en) 2013-04-24
US20140364387A1 (en) 2014-12-11
US20120058965A1 (en) 2012-03-08
US10330678B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
KR20160074015A (ko) 호르몬을 조절하기 위한 방법 및 시스템 및 관련 방법, 작용제 및 조성물
Finn et al. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice
CN103347517B (zh) 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
Jean-Yves et al. Voltage-gated ion channels, new targets in anti-cancer research
TW201202265A (en) Glucagon analogues
EA024147B1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
Kruse et al. Novel insights into M3 muscarinic acetylcholine receptor physiology and structure
Jin et al. Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp
Sharom Multidrug resistance protein: P‐glycoprotein
CN110305206A (zh) 一类双靶点多肽化合物及其在制备治疗糖尿病和以其为特征的病症的药物中的应用
JP2022536477A (ja) 非アルコール性脂肪性肝疾患、免疫不全、男性不妊症、及び血管疾患の治療のためのｓｗｅｌｌ１調節剤
US8133872B2 (en) Use of nicotinic acid adenine dinucleotide phosphate or derivative thereof as agent for treating type-2 diabetes
US11071731B2 (en) Allosteric modulators of the mu opioid receptor
Niu et al. Screening licorice for H2 receptor-binding anti-ulcer components using affinity chromatography
CN114555092B (zh) 胆汁酸及其衍生物在制备gpr39激动剂中的用途
Mitrovic Structural and biochemical characterization of GPR180 and its classification as a new member of the GOST protein family
Nakahara et al. A Sigma1 Receptor Agonist Alters Fluidity and Stability of Lipid Monolayers
Awosemo Development and Validation of LC− MS/MS Assay for 5-Amino-1-Methyl Quinolinium: Application to Pre-clinical Pharmacokinetic Studies
CN117177742A (zh) 溶酶体相关膜蛋白靶向化合物及其用途
WO2024113305A1 (zh) 阿扎那韦用于调节gpr119受体活性的用途
WO2025113170A1 (zh) 含有glp-1受体激动剂的经鼻给药的组合物及其制备方法与用途
BR102020015866A2 (pt) Peptídeos com atuação sobre o receptor hipotalâmico y5 com atividade supressora do apetite
Harris Ouabain regulates caveolin-1 vesicle trafficking by a Src-dependent mechanism
WO2021028346A1 (en) Tshr ligand binding domain and methods using said domain
Saloman Name: Jami Lynn Saloman Email: jsaloman@ gmail. com Degree and Date to be Conferred: Ph. D., 2012 Collegiate Institutions Attended: University of Maryland, Baltimore

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160613

Application number text: 1020137000152

Filing date: 20130103

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160617

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160703

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161201

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160703

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I